-
Sector Analysis
Magnetic Resonance Imaging (MRI) Systems Market Size by Segments, Share, Regulatory, Reimbursement, Installed Base and Forecast to 2033
Magnetic Resonance Imaging (MRI) Systems Market Report Overview The magnetic resonance imaging (MRI) systems market size was valued at $5.21 billion in 2023 and is forecast to grow at a CAGR of over 6% during the forecast period. MRI systems are non-invasive diagnostic imaging system that utilizes strong magnetic fields. It aids in the detection & diagnosis of various conditions and the assessment of the patient's progress. MRI is useful for examinations of soft tissues & nervous system. Magnetic Resonance...
-
Product Insights
NewLikelihood of Approval Analysis for Malignant Fibrous Histiocytoma
Overview How likely is it that the drugs in Malignant Fibrous Histiocytoma will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Malignant Fibrous Histiocytoma Overview Malignant fibrous histiocytoma, now termed undifferentiated pleomorphic...
-
Product Insights
NewPTCA Drug Coated Balloon (DCB) Catheters Pipeline by Development Stages, Segments, Region and Countries, Regulatory Path and Key Companies
PTCA Drug Coated Balloon (DCB) Catheters Pipeline Market Report Overview A Drug Coated Balloon (DCB) Catheter is an anti-restenotic drug coated PTCA balloon catheter intended to prevent re-narrowing of the coronary arteries. The PTCA Drug Coated Balloon (DCB) Catheters pipeline market research report provides a comprehensive understanding of the pipeline products along with their comparative analysis at various stages of development. The report also includes information about the territories wherein the clinical trials are in progress, the regulatory paths followed...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Golimumab in Type 1 Diabetes (Juvenile Diabetes)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Golimumab in Type 1 Diabetes (Juvenile Diabetes) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Golimumab in Type 1 Diabetes (Juvenile Diabetes) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Golimumab in Castration-Resistant Prostate Cancer (CRPC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Golimumab in Castration-Resistant Prostate Cancer (CRPC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Golimumab in Castration-Resistant Prostate Cancer (CRPC) Drug Details: Golimumab...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Upadacitinib ER in Alopecia Areata
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Upadacitinib ER in Alopecia Areata report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Upadacitinib ER in Alopecia Areata Drug Details: Upadacitinib (Rinvoq, Rim-Voq)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Upadacitinib ER in Vitiligo
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Upadacitinib ER in Vitiligo report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Upadacitinib ER in Vitiligo Drug Details: Upadacitinib (Rinvoq, Rim-Voq) is an...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Upadacitinib ER in Hidradenitis Suppurativa
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Upadacitinib ER in Hidradenitis Suppurativa report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Upadacitinib ER in Hidradenitis Suppurativa Drug Details: Upadacitinib (Rinvoq, Rim-Voq)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Upadacitinib ER in Oligoarticular Idiopathic Juvenile Arthritis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Upadacitinib ER in Oligoarticular Idiopathic Juvenile Arthritis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Upadacitinib ER in Oligoarticular Idiopathic Juvenile Arthritis Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Upadacitinib ER in Polyarticular Juvenile Idiopathic Arthritis (PJIA)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Upadacitinib ER in Polyarticular Juvenile Idiopathic Arthritis (PJIA) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Upadacitinib ER in Polyarticular Juvenile Idiopathic Arthritis...